Valuation check: 6744.TWO's profit margin is 7.58%, below the Healthcare sector average of 17.63%.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2026
Trailing 12 months ending Jun 2026
Feng Chi Biotech posts a profit margin of 7.58% as of June 2026. That compares with 12.15% in the prior-year period — down 37.6% year over year. That is below the Healthcare sector average of 17.63%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
In the prior comparable period, Feng Chi Biotech's profit margin was 12.15%. The latest reading is 7.58% — a 37.6% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.
For Healthcare stocks, a profit margin near 17.63% is typical. Feng Chi Biotech's 7.58% is lower that level. That is roughly 57.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
Feng Chi Biotech's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 7.58% as of June 2026; use YoY and peer views to separate noise from signal.
Context for 6744.TWO's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 17.63%), and (3) consistency with growth and profitability. This page covers the first two; Feng Chi Biotech's other metric pages and overview cover the third.